Mauro GaspariniView profile
Professor
Mauro Gasparini is a Full Professor at the Department of Mathematical Sciences (DISMA) of Polytechnic University of Turin. He serves as Director of DISMA since 2019, Member of Academic Senate, and co-leader in the SmartData@PoliTO Big Data Laboratory. His career spans academia and industry, including roles at Purdue University (Assistant Professor 1992-1996) and Novartis (Senior Statistician 1996-1998). He has been Editor of Biometrical Journal (2012-2015) and maintains referee activities across international journals. PhD from University of Michigan (1992, Dirichlet process applications) Academic leadership: Department Director, Editorial boards, ISTAT Advisor Research spans Bayesian methodology with biomedical applications Maintains collaborations with Novartis, Chiesi, and research centers His research interests focus on Bayesian inference , Biostatistics , and Clinical trials methodology, particularly addressing issues in pharmaceutical development, genomic data analysis, and medical decision-making. Recent work includes vaccine efficacy modeling, optimal imaging timing for cancer diagnostics, and adaptive trial designs. Key publication trends show interdisciplinary applications in Statistics in Medicine , Biometrics , and Statistical Methods in Medical Research , with emphasis on biomedical data science, Bayesian adaptive methods, and clinical decision support systems. Scientific contributions include: Editor, Biometrical Journal (2012-2015) Advisor, Italian National Institute of Statistics (2020-2024) Leadership in multiple research projects (NODES, SORGENTE, IDEAS) As PhD advisor, he supervises students in: Shaoshi Tang (Clinical trial modeling) Saeed Sani (Biomedical data analysis) Marco Ratta (Genomic statistics) Luca Rondano (Bayesian methods) Vittorio Zampinetti (Tumor DNA sequencing) Fulvio Di Stefano (Evidence-based decision statistical methods) He leads research projects in pharmaceutical statistics, genomic surveillance, and spatial risk assessment frameworks, with recent emphasis on SARS-CoV-2 analysis and cancer progression modeling.